On October 5, 2022 Biohaven reported the company officially launched as a newly independent company, spun out of its former parent as part of Pfizer’s $11.6 billion acquisition, which closed on Oct. 3 (Press release, Biohaven Pharmaceutical, OCT 5, 2022, View Source [SID1234643836]). Led by the same CEO, Vlad Coric, and publicly traded under the same stock ticker, the new Biohaven retains a pipeline of experimental medicines for a range of neurological disorders, four of which are already in clinical testing. It holds nearly $258 million in cash to fund its operations and no debt.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I am enthusiastic about continuing to lead our team in new, exciting directions as we strive to bring best-in-class therapies to patients for a broad range of diseases with few or no treatment options," said Coric in an Oct. 4 statement. "If past is prologue, this proven team will continue to succeed in achieving its mission for patients, shareholders and employees."

So far, investors appear to be giving Coric and his team some credit. Biohaven’s shares, which opened trading on Tuesday at a reset value of $7.30 per share, rose to more than $10 apiece by mid-morning on Wednesday, equating to a market value north of $700 million.

The new Biohaven’s most advanced drug candidate is a medicine called troriluzole, which is in late-stage testing for obsessive compulsive disorder and a genetic condition known as spinocerebellar ataxia, or SCA. In the latter condition, however, Phase 3 clinical trial results released in May showed the drug did not perform significantly better than placebo on the study’s main measure. The drug has previously failed studies in Alzheimer’s disease and in severe anxiety.

Biohaven isn’t giving up on SCA yet, focusing on a subset of patients who might benefit and signaling plans to continue regulatory discussions. But it’s focusing more on another drug, dubbed BHV-7000 and acquired via a $100 million deal earlier this year. That medicine is in testing for epilepsy as well as mood and pain disorders.

The company also has a drug for spinal muscular atrophy in Phase 3 testing, a multiple myeloma treatment in a Phase 1 study and half a dozen other discovery-stage programs.

On October 5, 2022 AIGEN Sciences, an artificial intelligence (AI)-based new drug development company, reported that it had completed attracting 4.2 billion won in investment through pre-Series A (Press release, AIGEN Sciences, OCT 5, 2022, View Source [SID1234643559]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Partners Investment, Blue Point Partners, Medytox Venture Investment, Quad Asset Management, and Korea University Technology Holdings participated in this investment.

Eisen Science will use this investment to advance artificial intelligence technology by expanding the virtual transcriptome map and to build an integrated platform including transcriptome/structure-based linked molecular design technology. In addition, the company plans to accelerate the development of its own anticancer drug and rare disease pipeline and recruit additional artificial intelligence, synthesis, and pharmacology/bio research personnel.

Eisen Science is an artificial intelligence (AI)-based new drug development company founded by Professor Jae-Woo Kang of Korea University in April last year. Eisen Science’s core new drug development artificial intelligence platform is an artificial intelligence technology based on transcriptome data, which can be used to screen and design drugs with new structures that induce transcriptome changes similar to knock down expression of disease targets. .

The company explained that transcriptome change-inducing drugs have the advantage of minimizing side effects caused by off-target effects of drugs, and can be applied to the development of treatments for intractable diseases for which the disease target is unknown by using the patient’s transcriptome information. am.

Jaewoo Kang, CEO of Eisen Science, said, "Through this investment, we plan to accelerate the development of our own new drug pipeline," adding, "We will develop lead substances in at least three pipelines by 2023 and create business development results with domestic and foreign pharmaceutical companies." "It is planned," he said.

Meanwhile, Igen Science has Vice President (CSO) Gwang-Ok Lee, who has been conducting research for 27 years at domestic pharmaceutical companies such as Hanmi Pharmaceutical, Bukwang Pharmaceutical, and Youngjin Pharmaceutical, and is in charge of planning, business development, and strategic partnerships for over 20 years at pharmaceutical companies such as SK Biopharmaceuticals, Chong Kun Dang, and Boryung. Vice President Kim Jong-ho (CBO) and others were recruited.

On October 5, 2022 Aptamer Science reported on the 5th that it decided to issue convertible bonds (CB) worth 16.5 billion won to secure clinical costs for developing innovative new drugs (Press release, Aptamer Sciences, OCT 5, 2022, View Source;idx=229 [SID1234641612]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The day before, Aptamer Science decided to issue the first bearer-type unsecured private convertible bond with interest. Both the coupon interest rate and the maturity interest rate are 0.0%, and the refixing (conversion price adjustment) condition is not included.

The company commented, "Despite the continuation of the high interest rate era, including the recent increase in the base interest rate, the market’s evaluation of the growth strategy appears to be positive, considering the fact that the interest rate is 0% and there is no refixing clause."

The company said, "Generally, in the case of convertible bonds (CB) issued in the KOSDAQ market, conditions for adjusting the conversion price according to the decline in the stock price are included," adding, "The exclusion of the refixing condition means that

"It can be interpreted that the possibility of stock conversion gains due to the rise in stock prices was highly evaluated," he emphasized.

Aptamer Science plans to use the funds raised this time to develop innovative new drugs, such as clinical trials for an anticancer drug (AST-201) for solid tumors and a follow-up pipeline immunotherapy drug (CD-25).

With the existing public offering funds, we plan to conduct large-scale prospective confirmatory clinical trials of a lung cancer early diagnosis kit based on blood protein biomarkers and target Asian markets such as Singapore through LDT (Laboratory Developed Test).

An Aptamer Science official explained, "Regarding the development of an innovative new drug, the anticancer drug (AST-201) was significantly delayed from the originally planned schedule due to problems such as securing raw materials due to the spread of COVID-19."

He continued, "Currently, a CDMO company is producing clinical samples, and as we aim to apply for an clinical trial (IND) in the second quarter of 2023, we plan to secure funds preemptively to accelerate the process."

Go to article: Aptamer Science attracts investment of 16.5 billion won… "We will speed up the development of new drugs"

On October 5, 2022 Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) ("Aesther"), a special purpose acquisition company ("SPAC") and Ocean Biomedical, Inc. ("Ocean"), a next-generation biopharma company reported that Aesther has entered into two separate Backstop Agreements for a total of up to $80 million, with the addition of up to $40 million from Meteora Special Opportunity Fund I, LP, Meteora Select Trading Opportunities Master, LP, and Meteora Capital Partners, LP (collectively, "Meteora") in connection with its proposed business combination (the "Business Combination" or the "Transaction") with Ocean (Press release, Ocean Biomedical, OCT 5, 2022, View Source [SID1234622465]). Previously, Aesther had executed and announced an up to $40 million Backstop Agreement with Vellar Opportunity Fund SPV LLC-Series 3.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Upon the closing of the Business Combination, Ocean will be a wholly owned subsidiary of Aesther, Aesther will change its name to Ocean Biomedical, Inc., and its common stock and warrants are expected to be listed on Nasdaq, under the symbols "OCEA" and "OCEAW," respectively.

The combined company will work to accelerate the development of Ocean’s core assets in oncology, fibrosis, and infectious diseases, all based on new target discoveries enabling first-in-class drug and vaccine candidates and developed through past and ongoing grants totaling $123.9 million.

Suren Ajjarapu, Chairman and CEO of Aesther, commented, "We are pleased to announce the execution of an up to $40 million Backstop Agreement with Meteora."

"Non-small cell lung cancer is the leading cause of cancer death and second most diagnosed cancer in the United States. Glioblastoma multiforme is a lethal type of brain tumor that affects approximately 28,000 people in the US, with a median survival time of about 15 months. The execution of up to $80 million in Backstop Agreements will help advance our cancer, fibrosis, and malaria discoveries into their Phase 1 trials, and has the potential to alleviate suffering and save thousands of lives," said Dr. Chirinjeev Kathuria, co-founder and Executive Chairman.

On October 5, 2022 EpiAxis Therapeutics reported at BioPharm America 2022, part of Biotech Week Boston, giving investors an update on the company’s progress in the epigenetic space (Press release, EpiAxis Therapeutics, OCT 5, 2022, View Source;utm_medium=rss&utm_campaign=epiaxis-presents-at-biopharm-america [SID1234621847]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BioPharm America is a conference where the new wave of life science innovators partner to fuel the future of drug development. Now in its 15th year, the event was held in-person on 28-29 September 2022 and across two digital days from 4-5 October 2022.

BioPharm America Digital created a robust exchange among executives from major pharmaceutical companies, biotechnology companies of every size and stage, investors and academic institutions. It brought dealmakers from the life science ecosystem together, with half the virtual audience from the United States and the rest from around the globe.

Appearing at BioPharm American follows an exciting Q1 FY23 for EpiAxis, which has included collaborations with University Health Network (UHN) and Peptilogics.

EpiAxis and UHN – Canada’s largest and leading research hospital – have entered into a collaboration to study a new approach to prostate cancer treatment; while Peptilogics, a biotech company engineering peptide therapeutics by combining computation and biology to improve the treatment landscape for patients with life-threatening diseases, has joined with EpiAxis to leverage AI for drug discovery to inhibit epigenetic oncology targets, aiming to reprogram cancer cells and drive immune reinvigoration.